Mission Statement, Vision, & Core Values of Novartis AG (NVS)

Are you curious about what drives one of the world's largest pharmaceutical corporations? With a 2024 revenue of $51.72 billion, how does Novartis AG stay focused and aligned?

Dive in to explore the mission statement, vision, and core values that guide Novartis in its quest to reimagine medicine and improve lives worldwide, and discover how these principles translate into tangible actions and financial results.

Let's explore the foundational principles that steer this global healthcare giant, which reported a $11.9 billion net income for 2024.

Novartis AG (NVS) An Overview of

Novartis AG, a global healthcare company, traces its origins to 1996 through the merger of Ciba-Geigy and Sandoz. With a history rooted in pharmaceuticals, the company develops and manufactures innovative medicines, eye care products, and generic pharmaceuticals. As of April 2025, Novartis continues to operate worldwide, offering treatments for a variety of diseases and conditions. The company focuses on innovative medicines and technologies that address critical health needs.

In its most recent financial reports, Novartis showcased strong financial performance. The company reported USD 45.4 billion in sales for 2023. Innovative Medicines generated USD 36.9 billion, growing 9%, while Sandoz contributed USD 9.1 billion. Key growth drivers included Entresto, with sales of USD 6 billion, growing 24%, and Kisqali, which reached USD 2.1 billion, up 75%. These figures underscore Novartis's strong market position and the success of its key products.

Novartis stands as a prominent leader in the global healthcare industry. Discover more about Novartis and its strategic moves: Exploring Novartis AG (NVS) Investor Profile: Who’s Buying and Why?

Novartis AG (NVS) Mission Statement

Novartis AG's mission is to 'reimagine medicine to improve and extend people’s lives.' This mission serves as a guiding principle for the company's strategic decisions and daily operations. It reflects a commitment to innovation, quality, and making a significant impact on global healthcare. The mission embodies the ambition to not only treat diseases but also to enhance the overall quality of life for patients worldwide.

The core components of Novartis's mission statement can be broken down into three key areas:

• Reimagining Medicine
• Improving People’s Lives
• Extending People’s Lives

Reimagining Medicine

“Reimagining medicine” highlights Novartis’s focus on innovation and pushing the boundaries of what is possible in healthcare. This involves:

• Research and Development: Novartis invests heavily in R&D to discover and develop new treatments. In 2024, Novartis invested $8.7 billion in Research and Development.
• Innovative Technologies: Embracing cutting-edge technologies to improve drug discovery, development, and delivery.
• Collaboration: Partnering with other organizations, research institutions, and healthcare providers to foster innovation and share knowledge.

Novartis focuses on transformative medicines, with 77% of its innovative medicines pipeline having the potential to be first-in-class or address significant unmet needs. This approach underscores their commitment to pioneering new treatments and therapies.

Improving People’s Lives

This component emphasizes the practical application of Novartis’s work. It is about making a tangible, positive impact on the health and well-being of individuals. Key aspects include:

• Access to Medicines: Ensuring that their medicines are accessible to patients who need them, regardless of their location or socioeconomic status.
• Patient-Centric Approach: Focusing on the needs and experiences of patients, involving them in the development of new treatments, and providing support and education.
• Quality Healthcare Solutions: Offering a range of products and services that address different healthcare needs and improve patient outcomes.

Novartis is committed to addressing global health challenges. For example, the company is actively involved in initiatives to combat diseases like malaria and is working to improve access to medicines in low- and middle-income countries.

Extending People’s Lives

This element of the mission reflects Novartis’s ambition to not only treat illnesses but also to help people live longer, healthier lives. This involves:

• Focus on Chronic Diseases: Developing treatments for chronic conditions such as cardiovascular diseases, cancer, and neurological disorders, which are major causes of mortality and morbidity worldwide.
• Preventive Care: Investing in research and development of preventive therapies and promoting healthy lifestyles to reduce the risk of disease.
• Healthcare Sustainability: Working to create sustainable healthcare systems that can support long-term health and well-being.

Novartis’s commitment to extending lives is evident in its oncology pipeline, which includes therapies aimed at improving survival rates and quality of life for cancer patients. They are also investing in areas like gene therapy, which holds the potential to provide long-lasting benefits for patients with genetic diseases.

The mission statement is more than just words; it is a call to action that drives the company’s strategic priorities and shapes its culture. By focusing on these three core components, Novartis aims to remain at the forefront of healthcare innovation and make a meaningful difference in the lives of people around the world. For additional insights into Novartis's financial performance and stability, you can explore Breaking Down Novartis AG (NVS) Financial Health: Key Insights for Investors.

Novartis AG (NVS) Vision Statement of

Novartis AG's mission is to reimagine medicine to improve and extend people’s lives. Its vision is to be a trusted leader in changing the practice of medicine. The company's core values include innovation, quality, collaboration, performance, courage, and integrity.

Novartis focuses on discovering, developing, and commercializing innovative treatments. As of fiscal year 2024, Novartis reported net sales of $45.7 billion and invested $9.9 billion in research and development. These figures underscore the company's dedication to its mission of transforming medicine through innovation. For more insights into the company's financial performance, you can explore this analysis: Breaking Down Novartis AG (NVS) Financial Health: Key Insights for Investors.

Novartis strives to address some of society's most challenging healthcare issues by discovering and developing breakthrough treatments and finding new ways to deliver them to as many people as possible. In 2024, Novartis received several key regulatory approvals, reinforcing its commitment to bringing innovative medicines to patients worldwide. The company's pipeline includes over 150 projects in various stages of development, reflecting its focus on addressing unmet medical needs.

The core of Novartis's mission involves enhancing the quality and duration of life. Novartis’s efforts span a wide range of therapeutic areas, including:

• Cardiovascular diseases
• Immunology
• Neuroscience
• Oncology

In 2024, treatments from Novartis impacted millions of patients globally. For example, the company's oncology drugs treated over 2.5 million patients. This broad reach highlights the tangible impact of Novartis's mission.

Novartis aims to be a leader in the healthcare industry, trusted by patients, healthcare professionals, and other stakeholders. The company actively engages in partnerships and collaborations to advance medical knowledge and improve patient outcomes. In 2024, Novartis invested $1.2 billion in collaborative research projects with academic institutions and other organizations. These collaborations are essential for driving innovation and ensuring that Novartis remains at the forefront of medical advancements.

Novartis's core values guide its actions and decisions. These values are fundamental to achieving its mission and vision:

• Innovation: Novartis invests heavily in research and development, with $9.9 billion spent in 2024, to discover and develop new medicines.
• Quality: The company is committed to maintaining high standards in the development, manufacturing, and distribution of its products.
• Collaboration: Novartis works with partners across the healthcare ecosystem to achieve shared goals.
• Performance: Novartis strives for excellence in all aspects of its business, delivering value to shareholders and stakeholders.
• Courage: The company encourages its employees to take calculated risks and challenge the status quo.
• Integrity: Novartis operates with the highest ethical standards, ensuring transparency and accountability.

Novartis AG (NVS) Core Values

Company's core values are central to its operations, influencing its corporate culture, strategic decisions, and interactions with stakeholders. These values reflect Company's commitment to innovation, ethical conduct, and improving global health outcomes. The core values guide the company in achieving its mission and vision, shaping its identity and distinguishing it in the pharmaceutical industry. You can read more about Company's mission and vision here: Novartis AG (NVS): History, Ownership, Mission, How It Works & Makes Money

Innovation

Innovation is a fundamental core value for Company, driving its efforts to discover, develop, and deliver novel medicines and healthcare solutions. Company invests heavily in research and development to address unmet medical needs and improve patient outcomes. In 2024, Company invested $8.4 billion in R&D, demonstrating its commitment to innovation. This investment supports a broad range of research activities, from early-stage discovery to late-stage clinical trials.

Examples of Company's commitment to innovation:

• Developing gene therapies for genetic disorders: Company has been at the forefront of developing gene therapies, such as Zolgensma, a treatment for spinal muscular atrophy. In 2024, Zolgensma generated sales of $1.47 billion, reflecting its impact on treating this rare disease.
• Advancing cancer treatment through targeted therapies: Company has made significant strides in cancer treatment through the development of targeted therapies and immunotherapies. For instance, Kisqali, a breast cancer drug, achieved sales of $2.08 billion in 2024, underscoring its importance in cancer care.
• Utilizing digital technology to improve healthcare: Company is leveraging digital technology to enhance drug development, patient care, and operational efficiency. In 2024, Company continued to expand its digital health initiatives, focusing on areas such as artificial intelligence and data analytics to improve decision-making and patient outcomes.

Quality

Quality is a critical core value for Company, ensuring that its products and services meet the highest standards of safety, efficacy, and reliability. Company adheres to strict quality control processes throughout its supply chain, from manufacturing to distribution, to ensure the integrity of its products. Company's commitment to quality is reflected in its compliance with regulatory requirements and its focus on continuous improvement.

Examples of Company's commitment to quality:

• Maintaining high manufacturing standards: Company invests in state-of-the-art manufacturing facilities and implements rigorous quality control processes to ensure the quality of its products. In 2024, Company invested in upgrading its manufacturing facilities to enhance efficiency and maintain high-quality standards.
• Ensuring regulatory compliance: Company is committed to complying with all applicable regulations and guidelines to ensure the safety and efficacy of its products. In 2024, Company worked closely with regulatory agencies to ensure the timely approval of its new medicines and therapies.
• Monitoring and addressing product quality issues: Company has robust systems in place to monitor and address any product quality issues that may arise. In 2024, Company promptly addressed and resolved any quality concerns, ensuring minimal impact on patients and customers.

Collaboration

Collaboration is an essential core value for Company, fostering partnerships and alliances to leverage expertise and resources to achieve common goals. Company collaborates with academic institutions, research organizations, and other companies to accelerate innovation and address complex healthcare challenges. Company's commitment to collaboration is reflected in its open innovation approach and its participation in industry initiatives.

Examples of Company's commitment to collaboration:

• Partnering with research institutions to advance scientific knowledge: Company collaborates with leading research institutions to advance scientific knowledge and accelerate the development of new medicines. In 2024, Company announced several new research collaborations, focusing on areas such as genomics and personalized medicine.
• Working with patient organizations to understand patient needs: Company engages with patient organizations to understand their needs and incorporate their perspectives into its drug development and patient support programs. In 2024, Company expanded its partnerships with patient organizations to enhance patient engagement and improve patient outcomes.
• Collaborating with other companies to develop new therapies: Company collaborates with other companies to develop new therapies and expand its product portfolio. In 2024, Company entered into strategic partnerships to co-develop and co-commercialize new medicines, leveraging the strengths of each partner.

Integrity

Integrity is a guiding core value for Company, ensuring that it conducts its business ethically and transparently. Company is committed to upholding the highest standards of ethical conduct in all its interactions with stakeholders, including patients, customers, employees, and shareholders. Company's commitment to integrity is reflected in its code of conduct and its compliance with anti-corruption laws.

Examples of Company's commitment to integrity:

• Adhering to ethical business practices: Company is committed to adhering to ethical business practices and complying with all applicable laws and regulations. In 2024, Company reinforced its commitment to ethical conduct through training programs and internal audits.
• Promoting transparency and accountability: Company promotes transparency and accountability in its operations, providing stakeholders with timely and accurate information. In 2024, Company enhanced its reporting practices to provide greater transparency into its financial performance and social impact.
• Ensuring compliance with anti-corruption laws: Company has robust systems in place to ensure compliance with anti-corruption laws and prevent bribery and corruption. In 2024, Company conducted thorough due diligence on its business partners to ensure compliance with ethical standards.

Respect

Respect is a fundamental core value for Company, fostering a culture of diversity, inclusion, and mutual respect. Company values the contributions of its employees and is committed to creating a workplace where everyone feels valued and respected. Company's commitment to respect is reflected in its diversity and inclusion initiatives and its employee engagement programs.

Examples of Company's commitment to respect:

• Promoting diversity and inclusion in the workplace: Company is committed to promoting diversity and inclusion in the workplace, creating a culture where everyone feels valued and respected. In 2024, Company launched several new diversity and inclusion initiatives, focusing on areas such as gender equality and racial equity.
• Supporting employee development and well-being: Company invests in employee development and well-being, providing employees with opportunities to grow and develop their skills. In 2024, Company expanded its employee wellness programs, offering resources and support to help employees manage their physical and mental health.
• Engaging with communities and stakeholders: Company engages with communities and stakeholders to understand their needs and contribute to their well-being. In 2024, Company supported various community initiatives, focusing on areas such as education and healthcare.